The clinical trial will assess the safety, tolerability, and immunogenicity of GLS-5700.
GLS-5700 is a synthetic DNA plasmid vaccine against the Zika virus. This is a Phase 1
clinical trial of this vaccine which encodes for the premembrane-membrane and envelope
regions of Zika virus.
Zika virus, first discovered in the Zika forest in 1947, has caused a large epidemic in South
America, Central America, and the Caribbean islands commencing in late 2014 or early 2015.
Zika virus can cause significant neurologic disease to include Guillain Barre Syndrome in
adults and microcephaly and other birth defects among children born to mothers who are
infected during pregnancy. At present no vaccines or treatments have been approved for Zika